Source:http://linkedlifedata.com/resource/pubmed/id/17959343
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2008-2-25
|
pubmed:abstractText |
Peripheral neuropathy is the most frequent neurological complication of human immunodeficiency virus (HIV)-1 infection and is commonly associated with the development of chronic pain. This open-label, 12-week pilot study assessed the efficacy, tolerability, and safety of a high-concentration capsaicin dermal patch (NGX-4010; capsaicin, 640microg/cm2, 8% w/w) to treat painful HIV-associated distal sensory polyneuropathy (DSP). Eligible patients had moderate-to-severe pain in both feet due to HIV-associated DSP or antiretroviral toxic neuropathy. Patients received a single 60-minute application of the investigational high-concentration capsaicin patch to the affected areas. The primary outcome measure was the mean percent change in numeric pain rating scale (NPRS) during weeks two to 12 postadministration. After a single 60-minute NGX-4010 application, the mean percent change from baseline in "average pain for past 24 hours" NPRS scores during weeks two to 12 was -40% (95% CI: -61%, -19%; P=0.0020). Similar results were observed for "worst pain for past 24 hours" and "pain now" scores. Eight of 12 patients (67%) were treatment responders (> or =30% pain decrease). Four of 12 patients (33%) experienced a > or =50% reduction in pain. Treatment was generally well tolerated. Treatment-associated pain was self-limited and could be managed with short-acting opioids. This study demonstrates that treatment of painful HIV-associated neuropathy with a single application of NGX-4010, a high-concentration capsaicin patch, was feasible, well tolerated, and associated with significant reduction in pain over the 12 weeks studied. No safety concerns were identified. Controlled studies of NGX-4010 for the treatment of painful HIV-associated neuropathy are warranted.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0885-3924
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
299-306
|
pubmed:dateRevised |
2008-7-1
|
pubmed:meshHeading |
pubmed-meshheading:17959343-Administration, Topical,
pubmed-meshheading:17959343-Adult,
pubmed-meshheading:17959343-Capsaicin,
pubmed-meshheading:17959343-Dose-Response Relationship, Drug,
pubmed-meshheading:17959343-Female,
pubmed-meshheading:17959343-Humans,
pubmed-meshheading:17959343-Male,
pubmed-meshheading:17959343-Middle Aged,
pubmed-meshheading:17959343-Pain,
pubmed-meshheading:17959343-Pilot Projects,
pubmed-meshheading:17959343-Polyneuropathies,
pubmed-meshheading:17959343-Sensory System Agents,
pubmed-meshheading:17959343-Treatment Outcome
|
pubmed:year |
2008
|
pubmed:articleTitle |
An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy.
|
pubmed:affiliation |
Mount Sinai School of Medicine, New York, NY 10029, USA. david.simpson@mssm.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|